相关实验视频
Updated: May 30, 2025

09:09
Lethality Bioassay Using Artemia salina L.
Published on: October 11, 2022
9.7K
来自Phlegmariurus carinatus的阿比坦二烯酸及其细胞毒性活动
Xi Chen1,2, Qiang Wang3,4, Dong-Kun Zheng5
1School of Pharmacy, Jiangxi Provincial Education Department Key Laboratory for the Application of Key Technologies in Drug Screening for Inflammatory Diseases and Phlegm Syndrome, Nanchang Medical College, Nanchang, China.
Natural product research
|January 30, 2025
概括
来自Phlegmariurus carinatus的两种新的阿比坦二特类药物显示出对质母细胞瘤细胞的潜在细胞毒性活性. 需要进一步的研究来评估它们的稳定性和有效性作为候选结质瘤药物.
科学领域:
- 自然产品 化学 化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- Phlegmariurus carinatus是一种因其潜在的药用特性而闻名的植物物种.
- 阿比坦二类是具有多种生物活性的一类天然化合物.
- 质母细胞瘤是一种侵袭性脑癌,治疗选择有限.
研究的目的:
- 从Phlegmariurus carinatus中分离和表征新的阿比坦二特类物种.
- 为了评估这些化合物的细胞毒性活动对U251质母细胞瘤细胞.
- 评估在各种条件下分离的化合物的稳定性.
主要方法:
- 使用色谱技术分离化合物.
- 使用综合光谱方法 (UV,IR,NMR,HRESIMS) 阐明结构.
- 对U251质母细胞瘤细胞系的细胞毒性测定.
- 高性能液体染色学 (HPLC) 用于稳定性研究.
主要成果:
- 成功分离了两种新的阿比二 (1和2) 和两种已知的类似物 (3和4).
- 化合物1-4对U251质母细胞瘤细胞表现出潜在的细胞毒性活动,IC50值在19.81至81.49μM之间.
- 这些化合物在保存条件下表现出相对稳定性,但在细胞培养基中的化过程中分解.
结论:
- 弗莱格马里乌鲁斯·卡里纳图斯 (Phlegmariurus carinatus) 是一种有前途的细胞毒性作用对抗质母细胞瘤的阿比二类药物的来源.
- 对作用机制和体内疗效的进一步研究是有必要的.
- 稳定性概况表明直接治疗应用存在挑战,需要进一步衍生或配方策略.
相关概念视频
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K

